Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inhibrx Biosciences Inc (NQ: INBX )

15.26 -0.37 (-2.37%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Inhibrx Biosciences Inc

< Previous 1 2 3 Next >
Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying
Via Benzinga
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
Via Benzinga
INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024
INBX stock results show that Inhibrx beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024
INBX stock results show that Inhibrx Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Top 4 Health Care Stocks That Are Preparing To Pump This Month
Via Benzinga
The NVDA Earnings Effect And What It Means For The Current Market Momentum
Discover the confluence zone that will make or break the S&P 500 and the preliminary supply (early distribution) you need to be aware of. 
Via Talk Markets
Topics Stocks
Exposures US Equities
JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know
Via Benzinga
Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients
Via Benzinga
Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move. 
Via Talk Markets
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency. 
Via Investor's Business Daily
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected... 
Via Benzinga
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO. 
Via Benzinga
$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday. 
Via Investor's Business Daily
Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate
Via Benzinga
$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying
Although US stocks closed slightly lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
Stocks Reverse Gains After ADP Report
Wall Street's rally has come to a screeching halt, as Treasury yields tick higher once again. 
Via Talk Markets
Why Is Inhibrx (INBX) Stock Soaring 45% Today?
Inhibrx received a vote of confidence from the Food and Drug Administration, skyrocketing the largely speculative INBX stock. 
Via InvestorPlace
Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge
Via Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
S&P 500 Rises 100 Points; Nasdaq Up 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. 
Via Benzinga
Nasdaq Surges 350 Points; Crude Oil Rises Sharply
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday. 
Via Benzinga
US Stocks Open Higher As Dow Jumps 550 Points
U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday. 
Via Benzinga
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Inhibrx Secures European Commission Orphan Medicinal Product Designation For Bone Cancer Candidate
The European Commission (EC) has granted orphan medicinal product designation to Inhibrx’s (NASDAQ: INBX) lead asset INBRX-109 for the treatment of chondrosarcoma. The regulatory grant was based on a... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.